First Trust Direct Indexing L.P. Takes Position in Integer Holdings Co. (NYSE:ITGR)

First Trust Direct Indexing L.P. purchased a new stake in shares of Integer Holdings Co. (NYSE:ITGR) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,656 shares of the medical equipment provider’s stock, valued at approximately $215,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. increased its holdings in Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 80 shares during the last quarter. Quest Partners LLC increased its holdings in Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC increased its holdings in Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Integer in the 1st quarter valued at approximately $106,000. Finally, Innealta Capital LLC acquired a new stake in Integer in the 2nd quarter valued at approximately $110,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ITGR. KeyCorp boosted their price target on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Citigroup boosted their price target on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Benchmark boosted their price target on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Truist Financial dropped their price target on shares of Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Piper Sandler restated an “overweight” rating and issued a $140.00 price target (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Integer has an average rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Stock Performance

Shares of ITGR stock opened at $128.68 on Wednesday. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average price of $128.02 and a 200 day moving average price of $121.53. The company has a market cap of $4.32 billion, a P/E ratio of 39.72, a PEG ratio of 1.82 and a beta of 1.09. Integer Holdings Co. has a 12 month low of $83.69 and a 12 month high of $133.53.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same quarter in the previous year, the firm posted $1.27 earnings per share. The company’s revenue was up 8.7% compared to the same quarter last year. Sell-side analysts predict that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.